Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Urodynamic Studies: Uroflowmetry

Urodynamic Studies: Uroflowmetry

Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Time Course of Drug Effect

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changes in Uropathogen Distribution in Relation to the COVID-19 Pandemic Timeline.

International urogynecology journal·2026

Same author

Systematic Review and Meta-Analysis of Bladder Wall Thickness for the Diagnosis of Detrusor Overactivity in Women.

International urogynecology journal·2026

Same author

How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI-RS 2025.

Neurourology and urodynamics·2026

Same author

Joint hypermobility syndrome for the urogynaecologist - A narrative review.

European journal of obstetrics, gynecology, and reproductive biology·2026

Same author

What Evidence Do We Need From Objective and Subjective Outcomes in Order to Recommend Specific Operative Procedures for Men to Relieve BPO and Women With SUI? ICI-RS 2025.

Neurourology and urodynamics·2025

Same author

Is There Adequate Evidence for Intracellular Bacteria Being a Significant Cause of rUTIs and Thereby Justifying Targeted Treatments Such as Bladder Fulguration or Intravesical Therapies? ICI-RS 2025.

Neurourology and urodynamics·2025

Search research articles

Related Experiment Video

Updated: May 28, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Vik Khullar¹, Jenelle Foote, Yodit Seifu

¹Urogynaecology Department, St Mary's Hospital, Imperial College, London, UK. vik.khullar@imperial.ac.uk

International Urogynecology Journal

|October 19, 2011

Summary

Darifenacin quickly improved overactive bladder (OAB) symptoms, including incontinence and urgency, within days. This rapid onset offers significant benefits for managing OAB effectively.

Related Experiment Videos

Last Updated: May 28, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Area of Science:

Pharmacology
Urology
Clinical Trials

Background:

Overactive bladder (OAB) significantly impacts patient quality of life.
Current OAB treatments aim to reduce symptoms like urinary incontinence and urgency.

Purpose of the Study:

To evaluate the time-to-effect of darifenacin in patients diagnosed with overactive bladder (OAB).

Main Methods:

Pooled efficacy and safety data from 1,059 patients in three 12-week double-blind studies.
Patients received either darifenacin (7.5 mg or 15 mg daily) or placebo.
Electronic bladder symptom diaries tracked micturitions, incontinence, and urgency; post hoc analysis focused on early timepoints.

Main Results:

Statistically significant improvements in most OAB symptoms were observed for both darifenacin doses compared to placebo by week 2.
Darifenacin demonstrated significant symptom reduction as early as days 6-8.
Improvements continued throughout the 12-week study duration.

Conclusions:

Darifenacin at 7.5 mg and 15 mg daily provides significant and rapid reduction in OAB symptoms.
The early onset of action is a clinically relevant benefit for patients with overactive bladder.
Darifenacin's rapid efficacy aids in the effective clinical management of OAB.